Posts about:
...who frequently use the drug and is associated with significant disability.
Mental Health | Too many questions about cannabis and cannabinoids remain unanswered for mental health clinicians to use them in clinical practice, a panel of researchers told an overflow crowd at the American Psychiatric Association Annual Meeting.
The presenters reviewed the medical literature on cannabis and cannabinoids relating to schizophrenia, anxiety disorders including social anxiety disorder, post-traumatic stress disorder, and other conditions.
Mental Health Update | The number of cannabis-associated emergency department (ED) visits has risen sharply since marijuana was legalized in Colorado.
New data show that although inhalable cannabis use accounts for most of these visits, edible cannabis is tied to a disproportionate number of visits, and patients present with different symptoms.
Just because you can get it, doesn't mean it is going to be safe for your long term health.
Knowledge and good sense matters.
"Historically, cannabis has predominantly been smoked using various implements such as joints, pipes, bongs, and blunts."
In any case, recreational marijuana has been legalized in nine states, and it seems likely that more are on the way.
People who haven't ever smoked pot—or maybe haven't since that one time they tried in college and spent 2 hours trying to define what a "corner" really is—may be trying it again. And when they try, they may use the new hotness of vaping to deliver THC into their bloodstream.
Now, thanks to researchers at Johns Hopkins, we have high-quality pharmacokinetic and pharmacodynamic data to suggest just what the reefer will do in that situation.
PF-04457845 is a selective, orally active, long-acting, time-dependent, and highly efficacious FAAH inhibitor that may decrease symptoms of cannabis withdrawal.
Because pot use by mothers and fathers carried similar risk, and a mother’s use before pregnancy had the same effect as use during pregnancy, the study team speculates that parental pot use is likely a marker for genetic and environmental vulnerability to psychotic experiences rather than a cause, and could be useful for screening kids at risk for psychosis later in life.
It was patented by the US Department of Health and Human Services in 2003 as an antioxidant and neuro-protectant. CBD has a complex mode of action which includes inverse agonism (functionally an antagonist) of CB1 and CB2 cannabinoid receptors, mild monoamine uptake inhibition, and 5-HT1A agonism.
Additionally, reviews based on preclinical and clinical research identify CBD as an anxiolytic, antipsychotic, anti-insomnia and antidepressant agent. Furthermore, it has putative anti-inflammatory, antidiabetic, analgesic, and neuroprotective properties.
Adjunct use of CBD in schizophrenia is supported by the highest quality of evidence.
A recent randomized controlled trial demonstrated superiority of adjunctive CBD to placebo in treating positive symptoms of schizophrenia, and a strong trend towards efficacy in addressing cognitive difficulties associated with this condition.
A prior randomized active control study found that monotherapy with CBD had comparable effect to amisulpride (one of the most efficacious antipsychotics) on positive symptoms while demonstrating a clear advantage in treating negative symptoms of schizophrenia. Several open-label studies extend and support the benefits of CBD in psychotic disorders.
Preclinical and open-label studies have found that CBD also may be helpful in the treatment of anxiety, particularly social anxiety, using a public speaking paradigm. Mostly preclinical evidence from animal studies suggests there may be a reason to study CBD as an adjunct treatment for depression, while preliminary evidence points to its potential usefulness as a safer substitute for controlled substances used in treating psychiatric and pain disorders.
While emerging evidence is encouraging, more studies utilizing rigorous scientific methodology and larger clinical samples need to be completed before we can endorse wider use of CBD in the treatment of psychiatric disorders.
which may explain the negative emotionality and higher risk of psychosis linked with the habit, according to a study published online in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.